Food Additive CAS 483-15-8 Dihydroberberine Powder Dihydroberberine

• Customization: Available
• Powder: Yes
• Customized: Negotiable
• Model NO.: QS-Dihydroberberine
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Product Name: Dihydroberberine
• Name: Dihydroberberine Powder
• Appearance: Yellow Powder
• Colour: Yellow
• Grade: Pharmaceutical Grade
• Assay: >99%
• Application: API
• Specific: COA
• Test Method: HPLC
• Mf: C20h19no4
• MW: 337.375
• Density: 1.37
• CAS: 483-15-8
• Melting Point: 223-224c(DEC.)
• Boiling Point: 557.8cat760mmhg
• Transport Package: Negotiable
• Specification: >99%
• Trademark: QS-Dihydroberberine
• Origin: Xian
• Production Capacity: 10000kg/Month

Product Description

Food Additive CAS 483-15-8 dihydroberberine Powder dihydroberberine

Product Description

Product Details

Product Name	Dihydroberberine
Appearance	White Powder
Assay	99%
MW	337.375
MF	C20H19NO4

Dihydroberberine can inhibit hERG channels, significantly reduce the expression of heat shock protein 90 (Hsp90) and its interaction with hERG. Dihydroberberine has anti-inflammatory, anti atherosclerosis, hypolipidemic and anti-tumor activities.

Application&Function

Dihydroberberine is an alkaloid and a derivative of berberine. It has a long history of application in traditional Chinese medicine and has attracted scientific attention in recent years due to its potential pharmacological activity. The main pharmacological effects of Dihydroberberberine are as follows:
Anti inflammatory effect: Dihydroberberberine can inhibit inflammatory response, which may be related to its regulatory effect on the NF - κ B signaling pathway. NF - κ B is an important transcription factor involved in inflammatory response, and its activation promotes the production of inflammatory mediators. By inhibiting the activation of NF - κ B, Dihydroberberberine can reduce the release of inflammatory cytokines, thereby alleviating the inflammatory response.
Anti atherosclerotic effect: Atherosclerosis is a chronic vascular disease, which is related to lipid metabolism disorder and vascular endothelial dysfunction. Dihydroberberine can prevent and treat the occurrence and development of atherosclerosis by improving endothelial function, regulating lipid metabolism and reducing oxidative stress.
Hypolipidemic effect: Dihydroberberberine can lower cholesterol and triglyceride levels in the blood, which is of great significance for the prevention and treatment of hyperlipidemia and related cardiovascular diseases. Its lipid-lowering effect may be related to its impact on fatty acid metabolism and regulation of liver lipid synthase activity.
Antitumor effect: Dihydroberberberine exhibits inhibitory effects on proliferation and induces apoptosis in various tumor cell lines. This may be related to its regulation of the cell cycle, regulation of apoptosis related proteins, and impact on the tumor microenvironment. In addition, Dihydroberberberine can enhance the killing effect of certain chemotherapy drugs on tumor cells.

Specification